主要真菌病原体获得性抗真菌药物耐药分子机制及EUCAST对其实验室检测与临床意义的指南
综述阐述主要人类真菌病原体获得性抗真菌耐药机制及检测工具。强调分子检测应作为培养药敏试验的补充,因现有分子 assay 可能未覆盖全部突变、耐药机制和靶基因。
要点
- 真菌培养慢且常无法培养,非培养分子方法在患者管理中日益重要。
- 分子方法可检测靶基因突变等预测抗真菌耐药的机制。
- 分子检测应补充而非替代培养药敏试验,因现有 assay 覆盖范围有限。
核心结论
- 分子方法检测耐药机制应作为培养药敏试验的补充,因临床分离株的突变、耐药机制和靶基因范围可能超出当前分子 assay 的覆盖。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 真菌培养通常比细菌慢且常无法培养,非培养分子检测在患者管理中日益重要且随技术进步更可靠。
- 分子方法可用于检测预测抗真菌耐药的靶基因突变或其他机制。
- 体外抗真菌药敏试验的国际指南执行不如细菌病原体广泛。
临床怎么用
- 实验室需熟练检测临床样本中的真菌病原体,通过识别获得性耐药分离株有效指导治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The increasing incidence and changing epidemiology of invasive fungal infections continue to present many challenges to their effective management. The repertoire of antifungal drugs available for treatment is still limited although there are new antifungals on the horizon. Successful treatment of invasive mycoses is dependent on a mix of pathogen-, host- and antifungal drug-related factors. Laboratories need to be adept at detection of fungal pathogens in clinical samples in order to effectively guide treatment by identifying isolates with acquired drug resistance. While there are international guidelines on how to conduct in vitro antifungal susceptibility testing, these are not performed as widely as for bacterial pathogens. Furthermore, fungi generally are recovered in cultures more slowly than bacteria, and often cannot be cultured in the laboratory. Therefore, non-culture-based methods, including molecular tests, to detect fungi in clinical specimens are increasingly important in patient management and are becoming more reliable as technology improves. Molecular methods can also be used for detection of target gene mutations or other mechanisms that predict antifungal drug resistance. This review addresses acquired antifungal drug resistance in the principal human fungal pathogens and describes known resistance mechanisms and what in-house and commercial tools are available for their detection. It is emphasized that this approach should be complementary to culture-based susceptibility testing, given the range of mutations, resistance mechanisms and target genes that may be present in clinical isolates, but may not be included in current molecular assays.
引用
- Rogers TR, Verweij PE, Castanheira M, et al. Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications. J Antimicrob Chemother. 2022. PMID: 35703391. doi:10.1093/jac/dkac161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。